NASDAQ:BNTX BioNTech (BNTX) Stock Price, News & Analysis → What’s Really Next for America… (From Porter & Company) (Ad) Free BNTX Stock Alerts $92.72 +1.05 (+1.15%) (As of 05/13/2024 ET) Add Compare Share Share Today's Range$92.41▼$93.4550-Day Range$86.17▼$96.3052-Week Range$85.21▼$125.83Volume249,316 shsAverage Volume646,020 shsMarket Capitalization$22.04 billionP/E Ratio185.44Dividend YieldN/APrice Target$118.82 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get BioNTech alerts: Email Address BioNTech MarketRank™ Stock AnalysisAnalyst RatingHold2.27 Rating ScoreUpside/Downside28.1% Upside$118.82 Price TargetShort InterestBearish1.55% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.30Based on 30 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.00) to ($1.59) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.19 out of 5 starsMedical Sector561st out of 925 stocksBiological Products, Except Diagnostic Industry86th out of 154 stocks 4.1 Analyst's Opinion Consensus RatingBioNTech has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on 4 buy ratings, 6 hold ratings, and 1 sell rating.Amount of Analyst CoverageBioNTech has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BioNTech's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.55% of the float of BioNTech has been sold short.Short Interest Ratio / Days to CoverBioNTech has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in BioNTech has recently increased by 16.77%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioNTech does not currently pay a dividend.Dividend GrowthBioNTech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BNTX. Previous Next 1.8 News and Social Media Coverage News SentimentBioNTech has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 30 news articles for BioNTech this week, compared to 9 articles on an average week.Search InterestOnly 16 people have searched for BNTX on MarketBeat in the last 30 days. This is a decrease of -41% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added BioNTech to their MarketBeat watchlist in the last 30 days. This is a decrease of -96% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioNTech insiders have not sold or bought any company stock.Percentage Held by Insiders19.20% of the stock of BioNTech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.52% of the stock of BioNTech is held by institutions.Read more about BioNTech's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioNTech are expected to grow in the coming year, from ($2.00) to ($1.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioNTech is 185.44, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 136.78.Price to Earnings Ratio vs. SectorThe P/E ratio of BioNTech is 185.44, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 167.19.Price to Book Value per Share RatioBioNTech has a P/B Ratio of 1.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about BioNTech's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyAmerica could fall from this eventAmerica’s “Internal Enemies” Exposed New documentary exposes a hidden election plan in Washington D.C. that, if successful, could be more financially and culturally devastating than the dot-com blowup of 2000, the 2008 financial crisis, or the COVID crash.Click here to see how you can protect yourself today. About BioNTech Stock (NASDAQ:BNTX)BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.Read More BNTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BNTX Stock News HeadlinesMay 13 at 2:42 AM | americanbankingnews.comQ2 2024 EPS Estimates for BioNTech SE (NASDAQ:BNTX) Increased by HC WainwrightMay 12 at 4:16 AM | americanbankingnews.comBioNTech (NASDAQ:BNTX) Price Target Increased to $113.00 by Analysts at HC WainwrightMay 11 at 10:33 AM | finance.yahoo.comWe Discuss Why BioNTech SE's (NASDAQ:BNTX) CEO Will Find It Hard To Get A Pay Rise From Shareholders This YearMay 11 at 5:58 AM | americanbankingnews.comBioNTech SE (NASDAQ:BNTX) Expected to Post Q1 2025 Earnings of ($2.31) Per ShareMay 11 at 1:34 AM | americanbankingnews.comBioNTech SE (NASDAQ:BNTX) Given Average Rating of "Hold" by BrokeragesMay 9, 2024 | americanbankingnews.comBioNTech (NASDAQ:BNTX) PT Raised to $98.00May 8, 2024 | markets.businessinsider.comDeutsche Numis Reaffirms Their Hold Rating on BioNTech SE (BNTX)May 8, 2024 | finance.yahoo.comBioNTech SE (NASDAQ:BNTX) First-Quarter Results: Here's What Analysts Are Forecasting For This YearMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for BioNTech Amid Strong Financials and Promising Oncology PipelineMay 8, 2024 | americanbankingnews.comBioNTech (NASDAQ:BNTX) Price Target Lowered to $122.00 at BMO Capital MarketsMay 8, 2024 | americanbankingnews.comBioNTech (NASDAQ:BNTX) Price Target Raised to $98.00 at TD CowenMay 7, 2024 | markets.businessinsider.comStrong Financials and Promising Oncology Pipeline Support Buy Rating for BioNTech SEMay 7, 2024 | msn.comBioNTech Reports Downbeat Earnings, Joins Medical Properties Trust And Other Big Stocks Moving Lower In Monday's Pre-Market SessionMay 7, 2024 | markets.businessinsider.comBuy Rating for BioNTech SE on Strong H2 Revenue Outlook and Promising Oncology PipelineMay 7, 2024 | markets.businessinsider.comBioNTech: Hold Rating Maintained Amidst Lower Q1 Earnings and Steady Revenue OutlookMay 7, 2024 | americanbankingnews.comBioNTech Target of Unusually Large Options Trading (NASDAQ:BNTX)May 6, 2024 | msn.comBioNTech Swings to First-Quarter Loss as Lower COVID-19 Commercial Sales Dents ToplineMay 6, 2024 | finance.yahoo.comWhat's Going With BioNTech Stock On Monday?May 6, 2024 | fool.comBioNTech Se (BNTX) Q1 2024 Earnings Call TranscriptMay 6, 2024 | investorplace.comBNTX Stock Earnings: BioNTech Misses EPS, Misses Revenue for Q1 2024May 6, 2024 | seekingalpha.comBioNTech SE 2024 Q1 - Results - Earnings Call PresentationMay 6, 2024 | investopedia.comBioNTech's Outlook Gives Vaccine Maker a Shot in the ArmMay 6, 2024 | barrons.comBioNTech Revenue Falls Sharply on Reduced Covid Vaccine SalesMay 6, 2024 | finanznachrichten.deBioNTech SE: BioNTech Announces First Quarter 2024 Financial Results and Corporate UpdateMay 6, 2024 | marketwatch.comBioNTech Swings to Net Loss on Lower Covid Vaccine SalesSee More Headlines Receive BNTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/20/2024Today5/13/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:BNTX CUSIPN/A CIK1776985 Webwww.biontech.de Phone49-61-31908-40Fax49-6131-908-4390Employees6,133Year Founded2008Price Target and Rating Average Stock Price Target$118.82 High Stock Price Target$171.00 Low Stock Price Target$90.00 Potential Upside/Downside+28.1%Consensus RatingHold Rating Score (0-4)2.27 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)$0.50 Trailing P/E Ratio185.44 Forward P/E RatioN/A P/E GrowthN/ANet Income$1.01 billion Net Margins4.01% Pretax Margin5.55% Return on Equity0.55% Return on Assets0.49% Debt Debt-to-Equity Ratio0.01 Current Ratio11.38 Quick Ratio11.16 Sales & Book Value Annual Sales$4.13 billion Price / Sales5.33 Cash Flow$5.13 per share Price / Cash Flow18.08 Book Value$92.17 per share Price / Book1.01Miscellaneous Outstanding Shares237,730,000Free Float192,083,000Market Cap$22.04 billion OptionableOptionable Beta0.25 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Ugur Sahin M.D. (Age 59)Co-Founder, CEO & Chair of the Management Board Comp: $1.23MDr. Ozlem Tureci M.D. (Age 57)Co-Founder, Chief Medical Officer & Member of Management Board Comp: $809.78kMr. Jens H. Holstein (Age 61)CFO & Member of Management Board Comp: $1.42MDr. Sierk Poetting Ph.D. (Age 51)MD, COO & Member of Management Board Comp: $832.18kMr. Ryan Richardson (Age 45)Chief Strategy Officer, MD & Member of Management Board Comp: $1.02MMr. Sean Marett (Age 59)Chief Business Officer, Chief Commercial Officer & Member of Management Board Comp: $803.38kDr. James Timothy Patrick Ryan Ph.D. (Age 49)Chief Legal Officer & Member of the Management Board Comp: $601.73kMr. Zach TaylorSenior Vice President of Corporate Development & StrategyDr. Katalin Kariko Ph.D.Senior VP & External Consultant for RNA Protein Replacement TherapiesDr. Oliver Henning Ph.D.Senior Vice President of OperationsMore ExecutivesKey CompetitorsargenxNASDAQ:ARGXNeurocrine BiosciencesNASDAQ:NBIXBio-TechneNASDAQ:TECHBiogenNASDAQ:BIIBQiagenNYSE:QGENView All CompetitorsInstitutional OwnershipClearbridge Investments LLCSold 144,879 shares on 5/13/2024Ownership: 0.152%O Shaughnessy Asset Management LLCSold 196 shares on 5/13/2024Ownership: 0.003%Covestor LtdBought 133 shares on 5/11/2024Ownership: 0.000%Mitsubishi UFJ Trust & Banking CorpSold 20,130 shares on 5/10/2024Ownership: 0.091%Acadian Asset Management LLCBought 37,792 shares on 5/10/2024Ownership: 0.047%View All Institutional Transactions BNTX Stock Analysis - Frequently Asked Questions Should I buy or sell BioNTech stock right now? 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last year. There are currently 1 sell rating, 6 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BNTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BNTX, but not buy additional shares or sell existing shares. View BNTX analyst ratings or view top-rated stocks. What is BioNTech's stock price target for 2024? 11 Wall Street research analysts have issued 1 year price targets for BioNTech's shares. Their BNTX share price targets range from $90.00 to $171.00. On average, they anticipate the company's share price to reach $118.82 in the next year. This suggests a possible upside of 28.1% from the stock's current price. View analysts price targets for BNTX or view top-rated stocks among Wall Street analysts. How have BNTX shares performed in 2024? BioNTech's stock was trading at $105.54 at the start of the year. Since then, BNTX shares have decreased by 12.1% and is now trading at $92.72. View the best growth stocks for 2024 here. When is BioNTech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our BNTX earnings forecast. How were BioNTech's earnings last quarter? BioNTech SE (NASDAQ:BNTX) released its quarterly earnings results on Wednesday, March, 20th. The company reported $2.05 earnings per share for the quarter, missing the consensus estimate of $2.64 by $0.59. The firm earned $1.59 billion during the quarter, compared to analysts' expectations of $2.04 billion. BioNTech had a trailing twelve-month return on equity of 0.55% and a net margin of 4.01%. What ETFs hold BioNTech's stock? ETFs with the largest weight of BioNTech (NASDAQ:BNTX) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM), Morningstar US Small Growth (MSGR), First Trust NYSE Arca Biotechnology Index Fund (FBT), Global X Genomics & Biotechnology ETF (GNOM), iShares Genomics Immunology and Healthcare ETF (IDNA), VanEck Biotech ETF (BBH), iShares Biotechnology ETF (IBB) and Franklin Genomic Advancements ETF (HELX). What guidance has BioNTech issued on next quarter's earnings? BioNTech issued an update on its FY 2024 earnings guidance on Monday, May, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.7 billion-$3.4 billion, compared to the consensus revenue estimate of $3.0 billion. What is Ugur Sahin's approval rating as BioNTech's CEO? 33 employees have rated BioNTech Chief Executive Officer Ugur Sahin on Glassdoor.com. Ugur Sahin has an approval rating of 89% among the company's employees. 81.0% of employees surveyed would recommend working at BioNTech to a friend. What other stocks do shareholders of BioNTech own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioNTech investors own include Moderna (MRNA), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Zoom Video Communications (ZM) and Advanced Micro Devices (AMD). When did BioNTech IPO? BioNTech (BNTX) raised $251 million in an initial public offering (IPO) on Thursday, October 10th 2019. The company issued 13,200,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink acted as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers. Who are BioNTech's major shareholders? BioNTech's stock is owned by a number of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (3.52%), Flossbach Von Storch AG (1.46%), Clearbridge Investments LLC (0.15%), Mitsubishi UFJ Trust & Banking Corp (0.09%), Simplex Trading LLC (0.00%) and IMC Chicago LLC (0.00%). How do I buy shares of BioNTech? Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does BioNTech have any subsidiaries? The following companies are subsidiares of BioNTech: Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, BioNTech RNA Pharmaceuticals, BioNTech Real Estate GmbH & Co. KG, BioNTech Real Estate Verwaltungs, BioNTech Research and Development, BioNTech Small Molecules, BioNTech USA Holding, JPT, TheraCode JPT, and reBOOST Management.Read More This page (NASDAQ:BNTX) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersGuard Against the Coming Financial UpheavalPorter & CompanyElon’s New Device is About to Shock the WorldInvestorPlaceConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe only AI company you should be looking atBehind the MarketsCharles Payne Demystifies OptionsUnstoppable ProsperityForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressGold ManiaStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioNTech SE Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
